Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.12 USD | +2.17% | -0.28% | -19.85% |
May. 30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
May. 30 | Bristol Myers: FDA approval for Breyanzi | CF |
ETFs positioned on Bristol-Myers Squibb Company
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.97% | 254 M€ | +13.69% | - | |
4.99% | 2 M€ | -.--% | ||
4.01% | 17 M€ | +6.09% | - | |
2.63% | 23 M€ | +14.32% | - | |
2.37% | 2 M€ | -25.75% | ||
2.29% | 31 M€ | +1.53% | - | |
2.08% | 9 M€ | -.--% | - | |
1.90% | 16 M€ | -3.37% | ||
1.85% | 2 M€ | -.--% | ||
1.43% | 5 M€ | -72.95% | - | |
1.42% | 9 M€ | -4.31% | - | |
1.37% | 26 M€ | +16.85% | - | |
1.26% | 800 M€ | +5.69% | ||
1.00% | 85 M€ | -0.54% | ||
0.99% | 9 M€ | +9.41% | ||
0.83% | 104 M€ | +9.50% | ||
0.82% | 8 M€ | +3.41% | ||
0.80% | 2,383 M€ | +13.18% | ||
0.78% | 3 M€ | +15.16% | - | |
0.78% | 13 M€ | -.--% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.85% | 81.59B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- BMY Stock
- Funds and ETFs Bristol-Myers Squibb Company